Latest fiscal year 2026 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2026, SONOMA PHARMACEUTICALS, INC. reported revenue of $20M, up 36.7% year over year. Operating margin was -12.6% and net margin -16.3%, on a free-cash-flow margin of -21.1% with capital expenditure at 1.0% of revenue. Every figure is computed directly from SNOA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2026 | $20M | -12.6% | -16.3% |
| FY2025 | $14M | -26.0% | -24.2% |
| FY2024 | $13M | -36.9% | -38.0% |
| FY2023 | $13M | -34.4% | -38.8% |
| FY2022 | $13M | -46.6% | -40.3% |
How does SNOA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.